Grifols (GIKLY) Income from Continuing Operations (2010 - 2020)

Grifols (GIKLY) posted Income from Continuing Operations of 330091015.77 for Q1 2020, down 55.46% quarter-over-quarter from 741176413.24 in Q4 2019, and up 69.41% year-on-year from 194843192.77 in Q2 2019.

Grifols (GIKLY) Income from Continuing Operations (2010 - 2020) Analysis & Trends

Grifols (GIKLY) has reported Income from Continuing Operations for 10 consecutive years, with 330091015.77 the latest figure, recorded in Q1 2020.

  • Income from Continuing Operations for Q1 2020 came in at 330091015.77, up 69.41% year-over-year; the trailing twelve-month figure through Mar 2020 was 2068492905.63 (up 40.69% YoY), and the FY2025 annual result was 582021757.35, up 155.71% from the prior year.
  • Income from Continuing Operations was 330091015.77 for Q1 2020 at Grifols, down from 741176413.24 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 882309060.91 in Q4 2017 and troughed at 101201471.58 in Q4 2016.
  • Average Income from Continuing Operations over 5 years is 338766834.04, with a median of 247880765.26 recorded in 2017.
  • Year-over-year, Income from Continuing Operations sank 154.07% in 2016 and soared 971.83% in 2017.
  • Over 5 years, Income from Continuing Operations stood at 101201471.58 in 2016, then jumped by 971.83% to 882309060.91 in 2017, then decreased by 9.06% to 802382283.85 in 2018, then slipped by 7.63% to 741176413.24 in 2019, then sank by 55.46% to 330091015.77 in 2020.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 330091015.77 in Q1 2020, 741176413.24 in Q4 2019, and 194843192.77 in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 833.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 2.71 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Grifols - - - -

Historic Data

Download Data
DateValue
Mar 31, 2020 330.09 Mn
Dec 31, 2019 741.18 Mn
Mar 31, 2019 194.84 Mn
Dec 31, 2018 802.38 Mn
Sep 30, 2018 546.22 Mn
Jun 30, 2018 208.87 Mn
Mar 31, 2018 264.14 Mn
Dec 31, 2017 882.31 Mn
Jun 30, 2017 157.93 Mn
Mar 31, 2017 247.88 Mn
Dec 31, 2016 -101.20 Mn
Sep 30, 2016 157.85 Mn
Jun 30, 2016 136.35 Mn
Mar 31, 2016 381.34 Mn
Dec 31, 2015 187.15 Mn
Sep 30, 2015 155.63 Mn
Jun 30, 2015 -43.48 Mn
Mar 31, 2015 221.20 Mn
Dec 31, 2014 -529.86 Mn
Sep 30, 2014 180.98 Mn